Roche's Tecentriq extended PFS in late-stage study in first-line NSCLC

A late-stage study demonstrated Tecentriq mixed with carboplatin and Abraxane cut risk of disease worsening or death, compared with chemo alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.

An OS benefit had not yet been observed.

Sandra Horning, Roche's chief medical officer and head of global product development, said: "Squamous non-small cell lung cancer is hard to treat and there have been limited new treatment options over the last few decades".

Atezolizumab - a PD-L1 inhibitor - is now approved for metastatic/unresectable urothelial carcinoma and metastatic NSCLC with EGFR or ALK mutations refractory to platinum-based chemotherapy.

Per the statistical analysis plan, Arm B (TECENTRIQ + carboplatin + nab-paclitaxel) must show a statistically significant effect on OS versus Arm C (carboplatin + nab-paclitaxel) before an analysis comparing OS and PFS between Arm A (TECENTRIQ + carboplatin + paclitaxel) and Arm C can be made.

Researchers can not compare arm A with arm C until an OS benefit is observed with arm B. The OS analysis is ongoing.

The safety profile of each agent was consistent with those previously reported; no new adverse events were reported when administered in combination. More mature data and findings will be presented at an upcoming oncology conference.